復星健康與衛寧健康達成戰略合作 建大灣區智慧醫療雲平台
復星醫藥(02196.HK)公布,旗下醫療健康科技公司上海復星健康科技與衛寧健康(300253.SZ)達成全面戰略合作,復星健康將藉助衛寧健康的技術優勢,啟動智慧醫療雲平台的建設,目標覆蓋復星健康旗下多家醫院,項目首期已在大灣區啟動部署,屆時將幫助用戶實現線上線下、院內院外、診前診中診後一體化的就診體驗。
根據戰略協議,雙方將在數字健康領域開展「醫-藥-險-康」聯動,促進醫療資源合理佈局、藥品安全流通、醫保商保融合與健康服務普及,並將積極開展聯合運營服務,成立聯合研究團隊,對醫療健康市場趨勢、技術運用、應用場景等進行前瞻性研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.